On May 8, 2025, Baird analyst Colleen Kusy released an update on Apellis Pharmaceuticals (APLS, Financial), maintaining an "Outperform" rating for the company. However, the firm adjusted the price target downward from $55.00 to $47.00, reflecting a 14.55% decrease.
Despite the revised target price, the maintained "Outperform" rating suggests continued confidence in the stock's potential performance relative to market peers. Investors should note the new price target while recognizing the retained positive outlook from Baird.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $38.75 with a high estimate of $75.00 and a low estimate of $18.00. The average target implies an upside of 115.40% from the current price of $17.99. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 23 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $227.76, suggesting a upside of 1166.04% from the current price of $17.99. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
